Investigating the effects of glucose-lowering and immunosuppressive therapies on immune response in diabetes and kidney disease
Official title: Evaluating the Effect of Hemodialysis Modality and New Anti-glycemic Drugs on NETosis on in Hemodialysis and Diabetic Patient, and Assessment of NETosis in Various Kidney Diseases
Run by Western Galilee Hospital-Nahariya · NCT06821919 · Data updated 2026-11-12
This study is testing if new diabetes medications can lower harmful immune responses in people with diabetes and kidney disease to help prevent serious complications.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Western Galilee Hospital-Nahariya Government |
| Locations | 1 site (Nahariya) |
| Status | Recruiting |
| Started | May 13, 2024 |
| Main results expected | December 30, 2030 |
| Study ends | December 30, 2031 |
| Registry record updated | February 12, 2025 |
| Trial ID | NCT06821919 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include diabetic patients aged 18 and older who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists, as well as chronic kidney disease patients with immune-mediated conditions.
✕Probably not a fit
Patients with acute infections, hematologic or oncologic diseases, or those who are positive for HIV or Hepatitis B/C may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the impact of new glucose-lowering medications, such as SGLT2 inhibitors and GLP-1 receptor agonists, on reducing NETosis in diabetic patients, which may help prevent complications like cardiovascular disease and kidney damage. Additionally, it will assess the effects of immunosuppressive therapies on NETosis in patients with immune-mediated kidney diseases, such as ANCA-associated vasculitis. By correlating NETosis activity with disease progression and treatment response, the study seeks to identify potential therapeutic strategies to improve clinical outcomes in both diabetes and chronic kidney disease.
Why it matters
Potential benefit: If successful, this study could lead to improved management of diabetes and kidney disease, reducing complications and enhancing patient quality of life.
How similar studies have gone: While the specific approach of this study is novel, previous studies have indicated that targeting NETosis may have beneficial effects in related conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: DM therapy study: - Diabetic patients aged 18 years or older (men and women). * Patients who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists. -Chronic kidney disease (CKD) patients :50 CKD patients with various etiologies. • Focus: * This part of the study will specifically evaluate immune-mediated kidney disease, such as ANCA-associated vasculitis, and the effects of immunosuppressive therapy on NETosis. • Exclusion Criteria: * Patients with acute infections, hematologic or oncologic diseases, or positive for HIV or Hepatitis B/C
Where it's running
-
Galilee Medical Center
Nahariya, Israel Recruiting
Study contacts
- Study coordinator: Etty Kruzel-Davila, MD
- Email: ETTYK@gmc.gov.il
- Phone: 972-4-9107619
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Cardiovascular, Kidney, and Metabolic Health Assessment with Patient Empowerment
This program will test whether an AI chatbot, large language model Copilot, and remote vital‑sign monitoring can help adults with diabetes, heart disease, or chronic kidney disease reduce their combined cardio‑kidney‑metabolic disease burden.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
-
SugarVita 2.0: a 12-week digital game for adults with type 2 diabetes
This 12-week pilot tests SugarVita 2.0, a serious digital game, to see if it helps adults with type 2 diabetes manage their condition and feel more confident.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.